The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of our immuno-oncology therapy for metastatic Merkel cell carcinoma in adults. We developed this therapy together with Pfizer.
The positive opinion from the CHMP is now being reviewed by the European Commission. We are expecting a decision in the third quarter of 2017.
Metastatic Merkel cell carcinoma is a rare and aggressive form of skin cancer. Currently there are only very few therapeutic options available for patients in Europe.
Together with Pfizer, we are also continuing to investigate the potential of the immunotherapy in other tumor types.
> News release